Status:
TERMINATED
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
Lead Sponsor:
Pfizer
Collaborating Sponsors:
ViiV Healthcare
Conditions:
HIV-1
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the protocol is to assess long-term safety and tolerability of subjects who discontinue for any reason from UK-453,061 qualifying studies.
Detailed Description
To assess long term safety and tolerability of subjects who discontinue for any reason from UK-453,061 studies. The study will also assess efficacy of the subsequent regimens in these patients. The tr...
Eligibility Criteria
Inclusion
- Previous participation in a qualifying study.
- Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
Exclusion
- Concurrent treatment in another clinical trial.
- Unwilling or unable to be followed for 12 months
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00824369
Start Date
July 1 2009
End Date
July 1 2013
Last Update
August 4 2014
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Sacramento, California, United States, 95814
2
Pfizer Investigational Site
Sacramento, California, United States, 95817
3
Pfizer Investigational Site
Miami, Florida, United States, 33137
4
Pfizer Investigational Site
Atlanta, Georgia, United States, 30308